Peptide comparisons

Both are next-generation metabolic peptides, but they are not the same bet.

These get grouped together in fat-loss discussion, but the evidence gap is large.

Both are next-generation metabolic peptides in active trials, but they work differently.

Tirzepatide hits two receptors (GLP-1 plus GIP) where Semaglutide hits one, and in head-to-head trials that second lever shows up as more weight lost on average and, for a lot of people, less gut nausea per pound dropped.

Retatrutide adds a third receptor (glucagon) on top of the GLP-1 and GIP that Tirzepatide already covers, and its trial numbers are the largest weight-loss figures anyone has published for this class.

Semaglutide works the GLP-1 satiety pathway; Cagrilintide works the amylin pathway.

This is the biggest generational gap in the GLP-1 space.

Two separate hunger switches.

These are close cousins, both come from the fat-loss tail of the HGH molecule and aim to trigger lipolysis without the full growth-hormone side effects.

Same drug class, different developers and timelines.

Semaglutide is the global GLP-1 standard, single-receptor, fully FDA-approved, years of real-world use.

Same mechanism, very different stage.

Two of the most-watched next-generation weight-loss compounds, both still in trials.

Semaglutide is the newer, stronger take on the same idea.

Two generations apart.

Different stage, and that is the whole story.

Two of the most-watched next-generation obesity compounds, and neither is approved yet.

Both put glucagon to work, just to different degrees.

Both raise growth hormone through the GHRH pathway, but they sit at very different evidence levels.

Ipamorelin tells the pituitary to fire a GH pulse; CJC-1295 (no DAC) makes each pulse bigger by mimicking GHRH.

The real split is oral versus injection.

HGH is the actual growth hormone, injected directly, which makes it the strongest lever and also the highest legal-risk compound in this space.

HGH is the hormone itself, injected, and it carries the heaviest legal risk in this catalog.

Both raise GH but from different angles.

Same mechanism (both are GHRH analogs), different weight class.

Both are GHRH analogs that restore natural GH pulses; the difference is in the molecule's stability.

Power versus cleanliness.

Two IGF-1 variants tuned for different reach.

HGH is the hormone itself, injected directly, the strongest GH lever and the highest legal-risk compound in this catalog.

These two aren't really an either/or.

Different targets entirely.

Two different healing layers.

Selank sits on the calm end, it takes the edge off anxiety without the sedation you'd get from a benzo.

Different angles on feeling settled.

MT-1 is the more selective, cleaner option: it drives pigmentation with fewer of the extra effects people complain about.

Two completely different routes to the same goal.

Both chase metabolic flexibility from different doors.

Same immune system, two different jobs.

Both come out of the Russian bioregulator tradition and both target aging, just at different spots.